Forbes contributor Sarika Bansal continues her discussion on Big Pharma’s role in combating NTDs. Take a look at her previous post, and read an excerpt of her current post:

“My last post discussed the reasons why neglected diseases have historically been neglected, the growing efforts to eradicate them, and why pharmaceutical companies should develop more drugs for them. Unfortunately, the traditional economics of drug development are stacked against neglected diseases, which disproportionally affect the world’s poorest populations. Drug development is a costly and time-consuming process, and even if a pharmaceutical company did develop a viable drug for a neglected disease, they would have virtually no way of recouping their investment.” Click here to read the full blogpost.